Fig. 6 | Scientific Reports

Fig. 6

From: Multi-omics analysis reveals inhibition of osteosarcoma progression by sporoderm-removed Ganoderma lucidum spores via targeting glycerophospholipid and fatty acid metabolism

Fig. 6

Working model of molecular mechanisms by which RGLS exerts its anticancer activity in osteosarcoma S-180 cells and xenograft tumors. On the one hand, RGLS promotes S-180 uptake of pla2g7 protein released by macrophages, which promotes the metabolism of PCs to produce LysoPCs with cytotoxicity. On the other hand, RGLS restructures fatty acid composition and compromises energy supply by inhibiting β-oxidation of long-chain fatty acid in S180 cells.

Back to article page